Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.
- 1 October 1996
- journal article
- research article
- Vol. 149 (4), 1167-75
Abstract
Hepatocellular carcinoma (HCC) is a heterogeneous disease. HCC derived from different stages of cellular differentiation may have different clinical and pathobiological behavior. To test the hypothesis that HCC can be classified into two types based on its phenotypic markers (hepatocellular and biliary differentiation), liver tissues from 290 Chinese patients with HCC were studied. Expression of hepatocytic differentiation marker (HEP-PAR-reactive antigen), biliary differentiation markers (AE1-AE3, cytokeratin-19), proliferation markers (Ki-67, proliferating cell nuclear antigen), alpha-fetoprotein, p53, and transforming growth factor-alpha in the tumor tissue were assessed by immunohistochemistry. Hepatocytic differentiation marker was detected in 99.7% and biliary differentiation markers were detected in 29.3% of these tumors. Clinically, no patient with HCC with biliary markers survived for more than 27 weeks compared with a 22.6% survival rate in patients with HCC negative for biliary markers. HCCs positive for the biliary differentiation markers showed features of more aggressive disease in terms of poorer cellular differentiation (P < 0.001) and high-level expression of proliferation markers (Ki-67, P < 0.001; proliferating cell nuclear antigen, P = 0.0114) compared with HCCs without biliary markers. HCCs with biliary markers also had a higher level of expression of alpha-fetoprotein (P < 0.001) and p53 (P = 0.0077). Classification of HCCs based on its phenotypic (differentiation) markers has both clinical and pathobiological implications.This publication has 38 references indexed in Scilit:
- Expression of hepatitis B surface and core antigens and transforming growth factor-a in “oval cells” of the liver in patients with hepatocellular carcinomaJournal of Medical Virology, 1994
- Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas-an enhanced immunohistochemical approachZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Parathyroid hormone‐related peptide expression in primary and metastatic liver tumoursHistopathology, 1993
- Immunohistochemical detection of proliferating cell nuclear antigen in hepatocellular carcinoma: Relationship to histological gradeJournal of Gastroenterology and Hepatology, 1993
- The stem cells of the liver ? a selective reviewZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Subclinical Hepatocellular Carcinoma in Hong Kong ChineseOncology, 1992
- p53 mutation in hepatocellular carcinoma after aflatoxin exposureThe Lancet, 1991
- Mutational hot spot in the p53 gene in human hepatocellular carcinomasNature, 1991
- Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern AfricaNature, 1991
- An autopsy study of hepatocellular carcinoma in hong KongPathology, 1980